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Human cytomegalovirus (HCMV) infection drives the phenotypic and functional differ-
entiation of NK cells, thereby influencing the responses of these cells after vaccina-
tion. NK cell functional differentiation is particularly advanced in African populations
with universal exposure to HCMV. To investigate the impact of advanced differentiation
on vaccine-induced responses, we studied NK-cell function before and after vaccina-
tion with Trivalent Influenza Vaccine (TIV) or diphtheria, tetanus, pertussis, inactivated
poliovirus vaccine (DTPiP) in Africans with universal, lifelong HCMV exposure. In con-
trast to populations with lower prevalence of HCMV infection, no significant enhance-
ment of NK-cell responses (IFN-γ, CD107a, CD25) occurred after in vitro re-stimulation
of post-vaccination NK cells with TIV or DTPiP antigens compared to pre-vaccination
baseline cells. However, both vaccinations resulted in higher frequencies of NK cells
producing IFN-γ in response to exogenous IL-12 with IL-18, which persisted for up
to 6 months. Enhanced cytokine responsiveness was restricted to less differentiated
NK cells, with increased frequencies of IFN-γ+ cells observed within CD56brightCD57−,
CD56dimCD57−NKG2C− and CD56dimCD57−NKG2C+ NK-cell subsets. These data suggest
a common mechanism whereby different vaccines enhance NK cell IFN-γ function in
HCMV infected donors and raise the potential for further exploitation of NK cell “pre-
activation” to improve vaccine effectiveness.
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 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
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Introduction
Natural killer (NK) cells are classically regarded as mediators
of innate immune responses, lysing infected or otherwise dis-
eased cells and secreting cytokines within hours to days of
initiation of an immune response [1]. However, NK cells can
also contribute as effector cells to adaptive immune responses
C© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
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by mediating antigen-specific antibody-dependent cellular cyto-
toxicity (ADCC) [2, 3] and producing IFN-γ in response to
interleukin-2 (IL-2) secreted by antigen-specific CD4+ T cells
[2, 4–7]. Moreover, it is recognized that NK cells undergo
intrinsic transformation as a result of infection or inflammation
[3, 8–11].
Recent evidence increasingly suggests that NK cells can dis-
play certain characteristics of immunological memory. How-
ever, this phenomenon has been described in different mod-
els. First, murine cytomegalovirus- and hapten-induced mem-
ory NK cells were described in human and mice [12, 13]. Sec-
ond, cytokine-induced memory-like NK cells generated through
the pre-activation of NK cells with interleukin (IL)-12/18/15
cytokines [14, 15]. Finally, “adaptive” NK cells mainly identi-
fied in HCMV infected individuals with increased expression of
CD57, leukocyte immunoglobulin-like receptor, and CD2 with
or without NKG2C as well as decreased CD161 and CD7 and
lack of the signaling adaptor FcɛRγI-, and transcription fac-
tors such as Syk, EAT-2 and promyelocytic leukemia zinc finger
(PLZF) [11, 16–18]. All of these scenarios demonstrate charac-
teristics of enhanced NK cell functionality post-infection and/or
stimulation.
We, and others, have shown that NK cells make a significant
contribution to vaccine-induced immune responses to intracellu-
lar pathogens, including viruses. In vitro stimulation of peripheral
bloodmononuclear cells (PBMC) from vaccinated individuals with
vaccine antigens including rabies [5], malaria [19], tetanus toxoid
[20], whole cell Bordetella pertussis [6], and inactivated influenza
virus [2, 6], results in NK cell degranulation (surface expression of
CD107a), IFN-γ production and upregulation of IL-2Rα/ CD25. NK
cell IFN-γ responses to vaccine antigens are enhanced after vacci-
nation with trivalent influenza vaccines, rabies or therapeutic HIV,
in a T cell IL-2 dependent process [2, 5, 7]. Moreover, antibod-
ies contribute to NK cell CD107a and CD25 expression through
formation of immune complexes and cross-linking of FcγRIII
(CD16) and these responses may also be enhanced by vaccination
[2, 21–23].
Different subpopulations (subsets) of NK cells contribute dif-
ferentially to vaccine driven responses. CD56bright and CD57−
NK cells are primarily activated to produce IFN-γ by exoge-
nous cytokines (including IL-2, IL-12, IL-15, IL-18, and IL-21
[20, 24–26]. CD56dimCD57+ NK cells respond less effectively
to cytokines (due, in part, to reduced expression of cell surface
cytokine receptors) [9] but secrete IFN-γ and become cytotoxic in
response to ligation of activating surface receptors such as natural
cytotoxicity receptors (NCRs) and CD16 [20, 25, 26]. Further-
more, the proportions of NK cells in each of these subsets varies
between individuals according to age, genotype and prior expo-
sure to infections [25–28].
In particular, human cytomegalovirus (HCMV) is a known
modulator of NK cell phenotype and function, predominantly
associated with ligation of the activating C-type lectin-like recep-
tor, CD94/NKG2C, by an HCMV peptide (UL40) bound to HLA-
E, but also with expansions of NK cells expressing activating
Killer cell Immunoglobulin-like Receptors (KIR) [10, 29–31].
HCMV-seropositive individuals accumulate “adaptive” NK cells,
which are mostly CD56dim, CD57+ and CD16bright, and fre-
quently (but not always) express NKG2C [3, 11, 29]. In keep-
ing with this phenotype, adaptively expanded NK cells are less
responsive to exogenous IL-12 and IL-18 but are highly efficient
mediators of ADCC (including killing of HCMV infected target
cells) and produce IFN-γ in response to cross-linking of CD16
[9, 11].
We have observed that NK cells from HCMV-seropositive
subjects make low frequency IFN-responses to killed or inacti-
vated pathogens or vaccine antigens and that responses are not
strongly enhanced by vaccination [2, 6, 20]. However, these
impacts of HCMV-infection are not only due to skewing of
NK cell populations towards an “adaptive” phenotype as IFN-
γ responses are lower in all NK subsets of HCMV seropositive
individuals when compared to HCMV seronegative individuals
[6].
The seroprevalence of HCMV increases with age and varies
enormously between populations [32, 33]. HCMV serostatus is
therefore likely to be a significant confounder of comparisons of
immune responsiveness over the life course and between popu-
lations. We have previously studied the phenotype and function
of NK cells in a Gambian population (age range 1 and 49 years)
where HCMV infection is essentially universal by the age of 12
months (>97% HCMV seropositive) [28]. In this population, dif-
ferentiation of NK cells from CD56bright through CD56dimCD57− to
CD56dimCD57+ occurs very early in life and is maximal by the age
of 10 years; acquisition of CD57 is often associated with expres-
sion of NKG2C and NK cell differentiation is delayed in individuals
lacking NKG2C due to a homozygous deletion of KLRC2, the locus
encoding NKG2C [28].
We therefore investigated whether NK cells from Gam-
bian children would produce IFN-γ in response to pathogen-
associated vaccines and whether vaccination would signifi-
cantly boost these responses. Moreover, we have recently
observed that vaccination can enhance NK cell IFN-γ responses
to exogenous cytokines (in a manner analogous to in vitro
“pre-activation” of NK cells by IL-12 and IL-18 [14, 15, 34]
in HCMV-seropositive but not HCMV-seronegative donors [2].
We therefore hypothesized that vaccination would enhance
NK-cell responsiveness to cytokines in this HCMV-infected
population.
We investigated the impact of two different vaccinations on
NK cell function and phenotype in The Gambia. First, we stud-
ied the NK cell response to primary vaccination with inacti-
vated, trivalent, seasonal influenza vaccine (TIV) in a previ-
ously unvaccinated, age-stratified cohort. Second, the NK cell
response to booster vaccination against diphtheria, tetanus, per-
tussis, and polio (DTPiP) was examined in adults who had been
vaccinated in infancy. We observed only limited enhancement of
TIV-driven T-cell-dependent NK-cell responses after vaccination
in all age groups. However, significant enhancement of vaccine
antigen independent responses to exogenous pro-inflammatory
cytokines was observed, persisting for at least 6 months after
vaccination.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Results
High HCMV seroprevalence in Gambian children and
adults
For the TIV study, complete sample sets (baseline, 1, 3, and 6
months post-vaccination) were obtained from 68 individuals; 22
children (2-6 years of age), 21 young adults (20-30 years or age)
and 25 older adults (60-75 years of age) (Table 1). Similar num-
bers of male and female subjects were recruited within each age
group (Table 1). As expected, HCMV was highly prevalent with
only one child and one elderly adult being seronegative (Table
1). Median anti-HCMV IgG concentrations were slightly, but not
significantly, higher in children than 20–30 year young adults
and were significantly higher among 60–75 year olds compared to
young adults, indicating potential HCMV reactivation in the oldest
individuals. The vast majority of subjects were also seropositive for
EBV infection with a tendency toward increasing seroprevalence
with increasing age but without any significant age-dependent
effect on EBNA-1 IgG titres (Table 1). Additionally, the overall fre-
quencies of individuals homozygous for the NKG2C wild type gene
was 44.1%; 42.6% were heterozygous and 13.2% were homozy-
gous for the NKG2C gene deletion (an allele frequency of 34.6%)
consistent with known frequency in The Gambia [35] (Table 1).
Age-related changes in NK-cell differentiation
phenotype
Both HCMV infection and age influence the differentiation and
function of NK cells and may therefore affect vaccine responses
[25, 26, 28]. PBMC collected at baseline (prior to vaccination)
from participants in the influenza studywere therefore analysed ex
vivo for NK cell (Fig. 1; flow cytometry gating strategies are shown
for NK cells in Supporting Information Fig. 1, blood myeloid and
lymphoid lineages in Supporting Information Fig. 2 and memory
T cells in Supporting Information Fig. 3).
The overall frequency of NK cells (CD3−CD56+) among the
peripheral lymphocyte population increased significantly with
increasing age (Fig. 1A) and, within the NK cell population, the
frequency of CD56bright NK cells was significantly higher among
children than among adults (Fig. 1B). While there was a gradated
increase in the frequencies of cells expressing the late differenti-
ation marker CD57 (Fig. 1C), similar frequencies of NKG2C+ NK
cells were observed at all ages (Fig. 1D). As expected, the fre-
quency of cells expressing NKG2A decreased, and the frequency
of cells expressing NKG2C increased, as NK cells differentiated
from CD56bright via CD56dimCD57− to CD56dimCD57+ (Fig. 1E
and F). No significant difference was observed in the frequency
of highly differentiated CD57+NKG2C+ NK cells between children
and adults in this cohort (Fig. 1E and F).
B-cell frequencies were significantly higher in 2–6 year-old
children than in adults and there was a tendency for the fre-
quencies of blood myeloid cell populations to increase with age
Figure 1. Age-dependent differences in NK-cell subsets. (A–F) Propor-
tions of NK cells and subsets were determined ex-vivo at baseline
for three age-defined groups (2–6, 20–30, 60–75 years). Proportions of
(A) CD56+CD3− NK cells within total lymphocytes and (B) CD56bright
cells within NK cells. Frequency of (C) CD57 and (D) NKG2C+ cells
within CD56dim NK cells. Expression of (E) NKG2A and (F) NKG2C within
CD56/CD57-defined NK cell subsets. Data are shown for 68 subjects.
Boxes indicate median values with interquartile ranges and whiskers
indicate 95th percentiles. Statistical analysis was performed on sam-
ples using (A–D) Kruskal–Wallis test, *p < 0.05, **p < 0.01, ***p < 0.001
and (E,F) using linear trend ANOVA with correction for multiple com-
parisons ****p < 0.0001.
(Supporting Information Fig. 2). While the overall proportion of
CD3+ T cells did not differ between age groups, both CD4+ and
CD8+ T cells differentiated toward effector memory cell popula-
tions with increasing age (Supporting Information Fig. 3). There
was a particularly marked accumulation of highly differentiated
CD28−CD57+CD4+ T cells in the oldest age group (Support-
ing Information Fig. 3, E), consistent with previous observations
in the elderly [36, 37]. While the proportions of CD28−CD57+
CD8+ T cells that were highest in the oldest age group, high
frequencies were also present in children, as observed previ-
ously by ourselves and others (Supporting Information Fig. 3, J)
[37, 38].
C© 2017 The Authors. European Journal of Immunology published by
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Effect of vaccination on NK-cell responses to influenza
vaccine antigens
Wehave previously observed, in UK subjects, that natural exposure
to influenza, or vaccination with TIV, promotes T-cell-dependent
NK-cell IFN-γ responses and antibody dependent NK cell degranu-
lation [2, 6]. Importantly, upregulation of CD25 and production of
IFN-γ by NK cells after in vitro restimulation with vaccine antigens
was consistently greater among HCMV seronegative than HCMV
seropositive subjects, whereas degranulation responses were rel-
atively unaffected by HCMV infection [2, 6]. Thus, given the very
high prevalence of HCMV infection in The Gambia (Table 1), we
hypothesized that vaccination of Gambian subjects with TIV might
potentiate antigen/antibody-induced degranulation responses but
not IFN-γ production. A potential exception to such a response pat-
tern could be in 2–6 year-old children, among whom the effects
of persistent HCMV infection may not yet be fully apparent.
In vitro re-stimulation of PBMC with TIV antigen revealed only
limited induction of IFN-γ and CD25 compared to the (back-
ground) response to adjuvanting low concentrations of IL-12+
IL-18 alone (Fig. 2A and C). Significant induction of NK cell
CD107a expression in response to TIV was, however, observed at
both baseline and all post-vaccination time points, although there
was no significant impact of vaccination (Fig. 2B). A similar pat-
tern of responses was observed to antigen alone, in the absence
of adjuvanting cytokines (data not shown). By comparison, NK
cells from both HCMV seropositive and seronegative UK subjects
made significant IFN-γ and CD25 responses to TIV, although these
were enhanced by vaccination only in HCMV seronegative donors
(Fig. 2D and F). Moreover, both HCMV seropositive and seroneg-
ative UK donors made more potent CD107a responses to TIV than
did the Gambian donors, although these were not enhanced after
vaccination (Fig. 2E). None of the responses to TIV differed sig-
nificantly between the different age groups of Gambian subjects,
potentially reflecting the very early functional differentiation of
NK cells in this population (Fig. 1) [28].
Similar patterns of NK-cell responses occurred in Gambian
adults vaccinated with DTPiP, with minimal NK-cell responsive-
ness to DTPiP antigens either before or after vaccination (data not
shown). Overall, these data are consistent with loss of antigen-
driven NK cell IFN-γ responses in HCMV seropositive individuals
while maintaining degranulation responses [6]. There was limited
induction of IL-2 from CD4+ T cells, which could, in part explain
the paucity of CD4+ T-cell-dependent NK-cell responses on re-
stimulation with influenza antigen in vitro (Supporting Informa-
tion Fig. 4).
Impact of post-vaccination antibody on vaccine
antigen-induced responses
Previous studies have shown a strong dependence of vaccine or
influenza virus-driven NK cell degranulation (and CD25 induc-
tion) on serum IgG antibodies [2, 6, 21, 22]. We therefore tested
sera collected after vaccination could promote or enhance vaccine-
antigen-driven NK-cell responses.
Anti-TIV IgG concentrations were significantly boosted by
vaccination in children (baseline, median 574 AEU/mL and
interquartile range (IQR) 460–653; 4 weeks, 1033 and 908–
1073) and in young adults (baseline, median 722 and 402–879; 4
weeks, 975 and 759–1104), whereas no significant increase was
observed in older adults (baseline, median 723 and IQR 622–
862; 4 weeks, 813 and 583–1031) (Fig. 3A–C). High median
levels of IgG were present at baseline in all age groups, consis-
tent with widespread natural exposure to influenza within the
study population. Similar anti-TIV specific antibody levels were
observed in a TIV vaccinated UK cohort (baseline, median titre
= 430, 299–767; 4 weeks, 962, 398–961). As shown for cells
cultured in pooled control sera (Fig. 2), strong degranulation
responses were observed in pre and post vaccination NK cells
cultured with autologous plasma collected either at baseline or
4 weeks after vaccination (Fig. 3D). Similar observations were
made in TIV vaccinated UK donors (Fig. 3E). However, no addi-
tional induction of CD107a expression was observed after vac-
cination, confirming that in both study cohorts, sufficient anti-
body was already present at baseline to drive these responses
(Fig. 3D and E). TIV-induced degranulation in Gambians was
associated with the down-regulation of CD16, which was further
enhanced in post-vaccination plasma, as previous described in
UK donors [22] (median, IQR for MFI of CD16: Medium alone:
Baseline plasma = 6539, 5137–7434; 4 weeks plasma = 5673,
5270–8823 and TIV: baseline = 1107, 810–1642; 4 weeks = 713,
562–1037, p = 0.0006).
Vaccination enhances NK-cell IFN-γ responses to
accessory cytokines
In UK subjects, influenza vaccination induces intrinsic changes
in NK cells characteristic of “pre-activated” NK cells; IFN-γ and
degranulation responses to exogenous cytokines were enhanced
after vaccination [2].
To assess whether enhancement of these responses also
occurred after TIV or DTPiP vaccination of Gambians with life-
long HCMV infection, pre and post-vaccination PBMC were cul-
tured with high concentrations of IL-12 (5 ng/mL) plus IL-18
(50 ng/mL) (HCC). Significant enhancement of NK-cell IFN-γ
responses to HCC were observed by 4 weeks after TIV vacci-
nation, which was stable and detectable for at least 24 weeks
(Fig. 4A). By comparison, the responses of UK donors were only
enhanced after vaccination for HCMV+ individuals, who had sig-
nificantly lower baseline HCC-stimulated IFN-γ production com-
pared to HCMV- individuals (Fig. 4B). In Gambians, this effect was
highly significant among 60–75 year old individuals (Fig. 4C).
9 of 21 individuals within the 2–6 year old age group showed
increased cytokine-driven responses after vaccination and were
categorized as vaccine ‘responder’ (median baseline IFN-γ pro-
duction: 2.8%, range 0–11%; 4 weeks: 8.3%, range 3.33-19.7%).
In contrast, ‘non-responder’ children showing no increase in IFN-γ
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 2. No change in NK cell responses to TIV after vacci-
nation. (A–F) Frequencies of IFN-γ (A, D), CD107a+ (B, E) and
CD25+ (C, F) NK cells were determined after in vitro stimula-
tion of PBMC from (A–C) TIV vaccinated Gambians at baseline
and 4, 12, and 24 weeks after vaccination. (D–F) Data from
HCMV seropositive and seronegative UK subjects at baseline
and 4weeks post TIV vaccination. Cells were cultured in (LCC)
low concentration of cytokines (rIL-12: & rIL18) alone (open
symbols) or LCC plus TIV vaccine antigen (closed symbols) (A–
F). Data are shown for (A–C) 61 TIV vaccinated Gambian and
(D–F) 52 UK subjects, comprising 19 HCMV+ and 33 HCMV-
individuals. Dots represent individual values and horizontal
lines represent themedian frequencies for each group. Paired
statistical analysis was performed using Wilcoxon signed-
rank test and comparisons between groups were made using
Mann–Whitney U test.*p < 0.05, **p < 0.01, ***p < 0.001,****p <
0.0001.
production had high baseline production (median 10.9%, range
2.04-22.8%) which tended to decrease after vaccination (median
6.0%, range 1.3-13.3%). Comparing the distribution of NK cell
subsets at baseline between these vaccine ‘responder’ and ‘non-
responder’ groups, individuals where boosting of the HCC driven
IFN-γ response was observed after vaccination tended to have
lower frequencies of CD57- cells at baseline, a trend also observed
for children alone (Fig. 4D and E).
Enhancement of responses to exogenous cytokines also
occurred 4 weeks after DTPiP booster vaccination in adults
(Fig. 4F). In contrast to previous observations in UK donors,
IL-12/IL-18-induced NK cell CD107a or CD25 expression was not
Figure 3. Vaccination does not enhance antibody-dependent, TIV-
driven NK cell responses. (A-C) Plasma IgG antibodies expressed as
Arbitrary ELISA Units (AEU)/mL were measured by ELISA against
TIV antigen for each age group. Dots indicate median antibody
levels and bars represent IQR. Data are shown for 68 subjects.
Repeated measures ANOVA was used to analyze the trend in anti-
body levels before and up to 24 weeks post-vaccination *p < 0.05,
***p < 0.001; ****p < 0.0001. (D, E) Frequency of CD107a expressing
NK cells at week 0 and week 4 post TIV vaccination of (D) Gambian
and (E) UK donors. Cells were in medium alone (open symbols) or
TIV antigen (closed symbols) in the presence of week 0 or week 4
autologous plasma. NK cells were gated as shown in Supporting
Information Fig. 1H,K. Data are shown for 38 Gambian subjects,
comprising 3 children, 17 adults and 18 elderly individuals (D) and
for 17 TIV vaccinated UK adults (E). Paired statistical analysis was
performed using Wilcoxon Signed rank test, *p < 0.05, **p < 0.01,
****p < 0.0001.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. NK cell IFN-γ responses to exogenous cytokines are sig-
nificantly enhanced post vaccination. (A-C) Frequencies of NK cells
expressing IFN-γ after restimulationwith IL-12+ IL-18 (HCC) before
and after vaccination with TIV in (A) Gambian and (B) UK donors.
(C) Age-stratified (2–6, 20–30, 60–75 years) NK cell IFN-γ responses
of Gambians to cytokines at baseline and 4 weeks after TIV vac-
cination showing the percentage of individuals within each age
group with enhanced responses post-vaccination. (D, E) Frequen-
cies of baseline CD57- NK cells across the entire cohort (D) or in
children only (E), split according to ‘responder’ individuals, with
increased HCC driven IFN-γ responses and ‘non-responder’. (F)
Responses to HCC in Gambian adults before and 4 weeks post-
vaccination with DTPiP. All NK cells analysis was gated as shown
in Supporting Information Fig. 1. Data from 65 subjects are shown
for TIV vaccinated Gambians (A, C), and 52 UK donors (compris-
ing 19 HCMV+, closed symbols and 33 HCMV- individuals, open
symbols) and from 18 Gambian subjects for DTPiP vaccination (F).
Dots represent the frequency of (A,B,C,F) IFN-γ+ or (C, D) CD57−
NK cells for each subject and horizontal lines represent median
frequency for each group. Statistical analysis of paired samples
(A, C, F) was performed using Wilcoxon signed-rank test and for
nonpaired analysis withMann–Whitney U test, *p< 0.05, **p< 0.01.
enhanced after either TIV or DTPiP vaccination (Supporting Infor-
mation Fig. 5A–D).
Vaccination-induced enhancement of IFN-γ pro-
duction among CD56bright and CD56dimCD57− subsets
As cytokine responsiveness varies by NK-cell differentiation status
[20], we analyzed the distribution of vaccine-enhanced responses
within NK-cell subsets. As expected, IFN-γ producing cells were
more frequent in the CD56bright NK cell subset than in the
CD56dimCD57+ NK cell subset, with intermediate frequencies
in CD56dimCD57− cells (Fig. 5A). Moreover, the proportion of
cells producing IFN-γ in response to IL-12/IL-18 was significantly
enhanced 4 weeks post-vaccination in both the CD56bright and
the CD56dimCD57− subsets but not in the CD56dimCD57+ sub-
set (Fig. 5A). Strikingly, when grouping NK cells according to
expression of CD57 and/or NKG2C, only the CD57−NKG2C− and
CD57−NKG2C+ CD56dim demonstrated increased frequencies of
IFN-γ producing cells after vaccination (4 weeks, p= 0.004) which
persisted up to 24 weeks (Fig. 5C). This enhancement was not
due to enrichment of CD57/NKG2C subsets, since no change was
observed in the proportions of CD56, CD57 and NKG2C-defined
subsets after vaccination (Supporting Information Fig. 5F). Sig-
nificant enhancement of cytokine-driven IFN-γ responses was also
observed within CD57- (NKG2C- or NKG2C+) NK cells for the 2–
6 and 60–75 year old age groups (Supporting Information Fig.
6). Consistent with the effects of TIV, DTPiP booster vaccina-
tion of adults resulted in significant enhancement of the IFN-γ
response to rIL-12/IL-18 among CD56dimCD57−NKG2C+ NK cells
(p = 0.009, 4 weeks) and there was a trend for enhanced respon-
siveness among CD56dimCD57−NKG2C− cells (Fig. 5D).
Figure 5. Enhancement of cytokine-driven IFN-γ pro-
duction within CD56bright, CD56dimNKG2C−CD57− and
CD56dimNKG2C+CD57− NK cells after vaccination. (A) Frequencies
of IFN-γ producing NK cells after HCC stimulation of PBMC at
baseline (0) and up to 24 weeks post TIV vaccination. (B) Gating
strategy showing CD57 and NKG2C-defined subsets. (C, D) Subset
distribution for NK cell IFN-γ production after HCC stimulation
of pre (0 weeks) and post-vaccination (4, 12, 24 weeks) samples
from subjects receiving (C) TIV and (D) DTPiP. Dots represent the
frequency of IFN-γ+ NK cells for each subject and horizontal lines
represent median frequency for each group. Statistical analysis
was performed on paired samples using Wilcoxon signed-rank
test, *p < 0.05, **p < 0.01.
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Discussion
In contrast to the enhancement of CD4 T-cell-dependent NK-cell
responses to vaccine antigens in previous studies of UK vacci-
nees [2, 5], we consistently failed to detect TIV or DTPiP vac-
cine antigen-driven NK cell IFN-γ or CD25 responses in Gam-
bian donors. Although antigen-driven CD107a responses were
detected, these were not boosted by vaccination. The very high
prevalence of HCMV among the Gambian population may par-
tially explain these observations since augmentation of NK cell
responses by vaccination was significantly more pronounced
among HCMV- than among HCMV+ UK subjects [2]. Nonethe-
less, the IFN-γ and CD25 responses to vaccine antigens among
NK cells from Gambian donors are typically much lower than
those of HCMV+ UK donors, suggesting that HCMV infection status
alone does not fully explain the lack of response after vaccination.
In addition, we have previously observed NK cell phenotypical
and functional discrepancies between HCMV+ Gambian and UK
donors (23). Further studies are required to determine whether
differences in the timing of HCMV infection, differences in strains
of infecting virus, or other factors including co-infections, might
explain this lack of vaccine antigen-driven NK function in Gam-
bians of all ages.
Despite the lack of “boosting” of antigen-induced NK cell
responses after vaccination in Gambian subjects, this study pro-
vides further evidence for enhancement of cytokine-driven NK
cell IFN-γ responses. TIV, DTPiP and likely other vaccines may
enhance these responses through a commonmechanism, with sim-
ilar mechanisms potentially underlying protracted enhancement
of NK cell responses after BCG booster vaccination in other African
populations [39] and in European populations after yellow fever
vaccination [40]. In this study, such vaccine-stimulated NK cells
persist for at least 6months whereas in our UK-based studies, these
effects were lost by 3 months. Possible explanations for this differ-
ence could be that responses in Gambian individuals are boosted
by more frequent exposures to environmental pathogens or that
the relative stronger responses of both HCMV− and HCMV+ UK
donors are less amenable to sustained enhancement.
Restriction of this effect to the CD56bright,
CD56dimCD57−NKG2C− and CD56dimCD57−NKG2C+ subset
of NK cells is reminiscent of the less differentiated NK cells
generated in vitro by cytokine pre-activation [14, 41]. Heightened
cytokine-driven IFN-γ responses within CD56dimCD57−NKG2C−/+
NK cells also suggests that these cells are equivalent to the less
differentiated CD57− cells observed in UK donors with enhanced
cytokine sensitivity and higher intrinsic proliferative capacity
(Ki67) after influenza vaccination [2]. These data are also
consistent with the acquisition of NKG2C, and expansion of
NKG2C+ cells, prior to functional differentiation and CD57 acqui-
sition [28]. Interestingly, TIV vaccinated individuals showing
enhanced responses to cytokines after vaccination tended to have
fewer cytokine-driven IFN-γ+ NK cells and of CD56dimCD57−
cells at baseline compared to those with no boosting. Differences
in cytokine driven responses observed at baseline were, however,
not attributable to ongoing environmental background activation
as we saw no differences in ex-vivo expression of CD25, CD107a
or IFN-γ comparing ‘responder’ and ‘non-responder’ groups. This
pattern of responses parallels that observed in UK subjects where
enhancement of cytokine driven responses after TIV vaccina-
tion occurs principally in HCMV+ individuals with suboptimal
baseline responses and not in HCMV- individuals, who already
have maximal frequencies of IFN-γ+ cells [2].
Differentiation subsets of NK cells could have varying thresh-
olds of cytokine (Interleukins-2, 12, 15, and 18) responsiveness,
thereby influencing the effective potency of the different cytokines
induced by vaccination. The acquisition of CD57 correlates with
decreased expression of IL-12Rβ2 and IL-18Rα [20]. However,
when comparing HCMV+ to HCMV− individuals we have observed
lower responsiveness within each CD57 defined subset, which can-
not be explained by cytokine receptor expression alone [2, 24].
Vaccine-induced enhancement of IFN-γ secretion in less dif-
ferentiated NK cells could reflect preferential proliferative expan-
sion, epigenetic modifications or a combination of both of these
processes. Epigenetic modifications have been demonstrated in
human and murine NK cells after cytokine pre-activation which,
in turn, promote increased IFN-γ transcription [42, 43]. One of
the limitations of this study is that, we had insufficient avail-
able paired pre and post-vaccination cells investigate whether
CD56dimCD57/NKG2C+ cells are particularly sensitive to vac-
cine induced epigenetic modifications. Examination of other NK
cell cytokines such as tumor necrosis factor-α and granulocyte-
macrophage colony-stimulating factor would also reveal whether
vaccine-induced enhancement is specific for IFN-γ production.
In summary, two very different vaccines are able to re-set
the threshold for human NK cell IFN-γ responses to cytokines
(in an antigen-independent manner) in individuals where HCMV
has had a major effect on NK-cell functional differentiation.
Enhancement of cytokine-driven NK-cell IFN-γ responses is par-
ticularly evident in elderly individuals and within a distinct
population of CD56dimCD57−NKG2C+ NK cells that accumu-
late in HCMV-infected individuals. This phenomenon may par-
tially compensate for the terminal differentiation of NK cells,
away from cytokine responsiveness, observed in HCMV seropos-
itive donors [3, 11, 25, 26, 28] and may also contribute to
the expansion of NKG2C+ NK cell populations that is observed
among HCMV-infected subjects after systemic viral infections
[44–47]. Vaccine-driven enhancement of effector functions in
CD56dimCD57−NKG2C− and CD56dimCD57−NKG2C+ NK merits
further investigation as a route to improve vaccine efficacy in
HCMV infected elderly individuals.
Materials and methods
Study subjects
The Medical Research Council Gambia (MRCG) Scientific Coordi-
nating Committee (SCC), The Gambia Government and MRCG
Joint Ethics Committee (SCC reference 1309), London School
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of Hygiene and Tropical Medicines Research Ethics Committee
(LSHTM reference 6237 and 6331) and The Republic of The Gam-
bia Medicines Board approved this study.
In order to minimize the impact of natural exposure to
influenza during the follow-up period, sample collection times
fell outside the main Gambian influenza season [48]. Following
written informed consent, 68 healthy participants were recruited
from three villages (Keneba, Manduar, and Kantong Kunda) in
West Kiang, The Gambia. Participants fell into one of three age
groups: 2–6, 20–30 and 60–75 years of age. Individuals with
chronic disease, infections, or influenza-like signs and symp-
toms during the previous 3 months or with an axillary temper-
ature of  38°C were excluded. Pregnant women, individuals
potentially allergic to vaccine products, and those with a his-
tory of previous influenza vaccination were also excluded. Venous
blood was collected at baseline (pre-vaccination) and partici-
pants were vaccinated intramuscularly with 2012–2013 north-
ern hemisphere, seasonal, trivalent inactivated influenza split
virion vaccine (Influenza A/California/7/2009 (H1N1) pdm09-
like virus; Influenza A/Victoria/361/2011 (H3N2)-like virus; and
Influenza B/Wisconsin/1/2010-like virus; Sanofi Pasteur MSD).
Subsequent blood samples were collected 1, 3, and 6 month(s)
post-vaccination.
For vaccination with tetravalent DTPiP, 18 adult males
between the ages of 21 and 29 years (median age = 24.2 years)
were recruited. All subjects previously received DTP and oral polio
vaccine as children and had not since been boosted. This study was
conducted in Sukuta, West Coast Region, The Gambia. A single
dose of DTPiP (RepevaxTM Sanofi Pasteur MSD) was given intra-
muscularly after collecting a baseline blood sample. A follow-up
blood sample was collected 4 weeks later.
Serology
Baseline samples from the influenza study were screened for
IgG antibodies to HCMV (Biokit, Barcelona, Spain) and IgG anti-
body against Epstein Barr virus (EBV) nuclear antigen-1 (EBNA-1)
(Euroimmun, Lubeck, Germany). Seropositivity was determined
according to HCMV- and EBV-negative standards provided by the
manufacturer. Influenza vaccine antigen-specific IgG was deter-
mined by an in-house ELISA as previously described [2, 6].
Cell preparation and culture
Peripheral Blood mononuclear cells (PBMC) were prepared by
centrifugation of whole blood over LymphoprepTM (Sigma, UK).
PBMC were reserved for ex vivo staining or cryo-preserved in
freezing medium (5% DMSO in Fetal Calf Serum, FCS) at -80°C
(1 × 107 PBMC per vial) overnight in Mr. FrostyTM Freezing Con-
tainers, prior to transfer into liquid nitrogen. Cells were recovered
by rapid thawing into culture medium and repeated washing, and
rested for 3 h prior to stimulation. Viability of recovered cells was
>95% and yields ranged from 30 to 65%.
In vitro restimulation assays were performed simultaneously
on cells from all pre and post vaccination time points for a given
individual. PBMC (3 × 105/ well) were cultured for 18 h in 96-
well U-bottom plates (Costar
R©
cell culture plates, USA) at 37°C,
5% CO2. For T-cell assays, cells were stimulated for a total of
5 h. TIV and DTPiP vaccine antigens were used at final concen-
trations of 2.5 and 0.5 μg/mL, respectively. Low Concentration
of Cytokines (LCC) comprised 12.5 pg/mL recombinant rIL-12
(Peprotech, London, UK)+ 10 ng/mL rIL-18 (R&D systems, Abing-
don, UK). High Concentration of Cytokine (HCC) comprised 5
ng/mL rIL-12+ 50 ng/mL rIL-18. GolgiStop, containing Monensin
and GolgiPlug, containing Brefeldin A (both from BD Biosciences,
Oxford, UK) were added after 2 h for T cell and after 15 h for NK-
cell assays. Culture medium was RPMI 1640 supplemented with
Penicillin-Streptomycin-Glutamine (Gibco, UK) and 10% pooled
human male AB serum (Sigma-Aldrich R©, Saint Louis, USA) unless
otherwise stated.
Flow cytometric analysis
For ex vivo antibody staining, cells plated at 3 × 105 cells/well
in a 96-well U-bottom plate. NK cell phenotype and function
was determined using CD56-PE-Cy7 (Clone NCAM-16.2), CD3-
V500 (Clone UCHT1), CD107a-FITC (H4A3), (all from BD Bio-
sciences, Oxford UK); NKG2C-PE (134591, R&D Systems, UK),
CD25-PerCP-Cy5.5 (BC96), CD57-e450 (TB01, both from eBio-
science/Affimetrix, UK), NKG2A-APC (Clone Z199, BeckmanCoul-
ter, UK). Anti-CD107a antibody was added at the initiation of
cell cultures as previously described [49]. T cell differentiation
and function were determined using combinations of CD3-V500,
CD45RA-APC-H7 (Clone HI100, BD Biosciences), CD4-PE (Clone
OKT4), CD8-PerCP-Cy5.5 (Clone RPA-T8), CD27-FITC (Clone
O323), CD28-PE-Cy7 (Clone CD28.2), CD57-e450 (All from eBio-
sciences) and CCR7-APC (150503, R&D systems). The relative
frequencies of T cells, B cells, monocytes, and myeloid/ plas-
mocytoid dendritic cells were determined using CD56-PE-Cy7,
CD3-V500 (Both from BD Biosciences), CD45-FITC (Clone HI30),
CD11c-PE (Clone 3.9), CD19-PerCP-Cy5.5 (Clone HIB19), CD123-
e450 (Clone 6H6), CD14-APC-e780 (Clone 61D3) (all from eBio-
science/ Affimetrix). Intracellular staining of NK cells and T cells
was performed after fixation and permeablisation (BD Bioscience)
and addition of IFN-γ-APC-e780 (Clone 4SB3, eBiosciences) or
anti-IFN-γ APC (Clone B27, BD Biosciences) and anti-IL-2 PE
(Clone MQ17-H12, BD Biosciences), respectively. Samples were
acquired on a Cyan ADP flow cytometer with Summit R© software
(influenza vaccine study), or LSRII or LSRIII Fortessa flow cytome-
ter with FacsDiva R© software (DTPiP vaccine study). All FACS data
analyses were performed using FlowJo R© (TreeStar). Where less
than 100 events were obtained within a gated NK cell subset, that
sample was excluded from the analysis.
Statistical analysis
Nonparametric Wilcoxon matched paired tests were used for
intra-group comparisons between pre and post vaccination data.
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Kruskal–Wallis tests were used for unpaired comparisons between
age groups, for nonpaired analysis Mann–Whitney U test was used.
Linear trend analyses were performed using repeated measures
ANOVA. GraphPad Prism (GraphPad Software 6) was used for
statistical analysis. Significant differences are reported as *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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